Quick Answer
ADC Therapeutics SA reported Net Income of -$142.62 million for fiscal year 2025.
ADC Therapeutics SA Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$142.62M | +9.6% |
| 2024 | -$157.85M | +34.2% |
| 2023 | -$240.05M | -52.8% |
| 2022 | -$157.13M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$40.97M | +6.8% | +27.7% |
| June 30, 2025 | -$56.65M | -55.0% | -46.7% |
| March 31, 2025 | -$38.60M | +17.2% | +12.2% |
| September 30, 2024 | -$43.97M | +5.9% | -20.3% |
| June 30, 2024 | -$36.54M | +25.3% | +21.6% |
| March 31, 2024 | -$46.61M | +21.5% | +0.3% |
| September 30, 2023 | -$46.73M | — | +4.5% |
| June 30, 2023 | -$48.92M | — | +17.6% |
- ADC Therapeutics SA showed an increase of +9.6% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, ADC Therapeutics SA’s net income has grown by 9.2% (from -$157.13 million to -$142.62 million).
- The most recent figure is from ADC Therapeutics SA’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: